ArticleHistopathology2025
Collagenous colitis in patients treated for cancer: role of immune checkpoint inhibitors. Clinical, histological and immunological features in 15 cases.
Article in Histopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsCollagenous colitis is a rare complication of immunotherapy for cancer. We report here 15 cases in order to assess the role of immune checkpoint inhibitors (ICI) in the onset of this disease, describe the histopathological and immunological features of this entity and compare them with 'idiopathic' collagenous colitis.
methodsWe retrospectively checked for all diagnoses of collagenous colitis from 2000 to 2024 in our tertiary cancer centre. Clinical charts and the available histopathological material were reviewed. Immunohistochemical profiling was performed to characterize immune cell populations (CD3, CD4, CD8, CD20, CD68, CD163, CD117, PD1 and PD-L1). A control group of 14 patients without cancer history was included for comparison.
resultsFifteen cases, diagnosed between 2017 and 2024, were included in the study group. There were nine male and six female, aged 23-81. Fourteen were treated by ICI (anti-PD1/PD-L1 in 13 cases, anti-CTLA4 in 1), 1 by daratumumab. All presented chronic diarrhoea. The typical histological features of collagenous colitis were present: sub-epithelial band of thickened extracellular matrix, expansion of the lamina propria. The predominant immune cell population was CD8+ T-lymphocytes in 12 cases. ICI-treated patients showed higher neutrophilic infiltration, including crypt abscesses and higher macrophage amounts than control patients.
conclusionCollagenous colitis in patients treated for cancer is closely associated with the use of anti-PD1/PD-L1 antibodies and shows some distinctive characteristics. A further understanding of the consequences of the PD1/PD-L1 axis blockade may shed further light on the pathogenesis of this rare disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.